注射用卡瑞利珠单抗 | China Drugs ListCamrelizumab for injection | China Drugs List

本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

商品名: 艾瑞卡Airuika
企业: 江苏恒瑞医药Jiangsu Hengrui Pharmaceuticals
药品类型: 生物药Biologic
治疗领域: 肿瘤科Oncology
公开来源记录的适应症: 肝细胞癌：①既往接受索拉非尼和/或仑伐替尼和/或含奥沙利铂系统化疗的晚期患者；②联合阿帕替尼用于不可切除或转移性肝细胞癌一线治疗。非小细胞肺癌：①联合培美曲塞和卡铂，用于EGFR突变阴性、ALK阴性、不可手术切除的局部晚期或转移性非鳞状NSCLC一线治疗；②联合紫杉醇和卡铂用于局部晚期或转移性鳞状NSCLC一线治疗。食管鳞癌：①既往一线化疗后进展或不可耐受的局部晚期或转移性患者；②联合紫杉醇和顺铂用于不可切除局部晚期、复发或转移性患者一线治疗。鼻咽癌：①既往二线及以上化疗后进展或不可耐受的晚期患者；②联合顺铂和吉西他滨用于局部复发或转移性患者一线治疗。宫颈癌：①联合法米替尼用于含铂化疗失败且未接受过贝伐珠单抗的复发或转移性患者；②联合法米替尼用于经充分验证检测确认PD-L1阳性（CPS≥1）的复发或转移性患者一线治疗。Hepatocellular carcinoma: (1) advanced disease after sorafenib and/or lenvatinib and/or oxaliplatin-containing systemic chemotherapy; (2) with apatinib as first-line treatment of unresectable or metastatic disease. NSCLC: (1) with pemetrexed and carboplatin as first-line treatment of EGFR mutation-negative, ALK-negative unresectable locally advanced or metastatic nonsquamous NSCLC; (2) with paclitaxel and carboplatin as first-line treatment of locally advanced or metastatic squamous NSCLC. Esophageal squamous cell carcinoma: (1) locally advanced or metastatic disease that has progressed after or is intolerant of first-line chemotherapy; (2) with paclitaxel and cisplatin as first-line treatment of unresectable locally advanced, recurrent or metastatic disease. Nasopharyngeal carcinoma: (1) advanced disease that has progressed after or is intolerant of two or more lines of chemotherapy; (2) with cisplatin and gemcitabine as first-line treatment of locally recurrent or metastatic disease. Cervical cancer: (1) with famitinib for recurrent or metastatic disease after failure of platinum-based chemotherapy, without previous bevacizumab treatment; (2) with famitinib as first-line treatment of recurrent or metastatic PD-L1-positive disease (CPS >=1), confirmed using a fully validated test.
适应症来源与口径: 来源日期： 2026-07-14, 2026-10-23. 生产商面向中国大陆的药品说明书。证据核查日期：2026年10月23日。Source date(s): 2026-07-14, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
说明书信息局限: 已取得完整官方药品说明书。中国大陆说明书。生产商原始页面图像已按顺序保存。Complete official prescribing information obtained. Mainland China label. Original manufacturer page images have been preserved in order.
中国可获得性状态: 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
海外状态: 待逐一核查各市场。Market-by-market verification pending.
医保分类: 已纳入国家医保（乙类）Included in national insurance (Category B)
医保版本: 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
医保限制: 限：1.既往接受过索拉非尼治疗和/或仑伐替尼治疗和/或含奥沙利铂系统化疗的晚期肝细胞癌患者的治疗；2.联合培美曲塞和卡铂适用于表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的、不可手术切除的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)的一线治疗；3.既往接受过一线化疗后疾病进展或不可耐受的局部晚期或转移性食管鳞癌患者的治疗；4.既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗；5.联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗；6.联合紫杉醇和顺铂用于不可切除局部晚期/复发或转移性食管鳞癌患者的一线治疗；7.联合紫杉醇和卡铂用于局部晚期或转移性鳞状非小细胞肺癌患者的一线治疗；8.联合甲磺酸阿帕替尼用于不可切除或转移性肝细胞癌患者的一线治疗；9.联合苹果酸法米替尼治疗既往经过含铂化疗但未经过贝伐珠单抗治疗的复发或转移性宫颈癌患者。Restricted to: (1) advanced hepatocellular carcinoma after sorafenib and/or lenvatinib and/or oxaliplatin-containing systemic chemotherapy; (2) use with pemetrexed and carboplatin as first-line treatment of EGFR mutation-negative, ALK-negative unresectable locally advanced or metastatic nonsquamous NSCLC; (3) locally advanced or metastatic esophageal squamous cell carcinoma that has progressed after or is intolerant of first-line chemotherapy; (4) advanced nasopharyngeal carcinoma that has progressed after or is intolerant of two or more lines of chemotherapy; (5) use with cisplatin and gemcitabine as first-line treatment of locally recurrent or metastatic nasopharyngeal carcinoma; (6) use with paclitaxel and cisplatin as first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma; (7) use with paclitaxel and carboplatin as first-line treatment of locally advanced or metastatic squamous NSCLC; (8) use with apatinib mesylate as first-line treatment of unresectable or metastatic hepatocellular carcinoma; (9) use with famitinib malate for recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not bevacizumab.
医保期限: 2026-01-01 至 2026-12-312026-01-01 to 2026-12-31
医保核查说明: 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

来源

打开交互详情、公开价格与讨论